Literature DB >> 24374044

Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: a meta-analysis.

Min Zhang1, Jing Ni1, Wang-Dong Xu1, Peng-Fei Wen1, Li-Juan Qiu1, Xiao-Song Wang1, Hai-Feng Pan1, Dong-Qing Ye2.   

Abstract

OBJECTIVE: The aim of this study was to determine whether CTLA-4 gene variants were associated with susceptibility to inflammatory bowel disease (IBD).
METHODS: Meta-analysis was conducted on the association between CTLA-4 variants and IBD using: (1) allelic contrast, (2) the recessive model, and (3) the dominant model.
RESULTS: A total of 9 relevant studies including 1739 Crohn's disease (CD) cases, 10 relevant studies containing 1017 ulcerative colitis (UC) cases and 2685 healthy controls were involved in this meta-analysis. Overall, CTLA-4+49A/G, -318C/T and CT60 variants were not associated with IBD susceptibility in all genetic models (P>0.05). Stratification by ethnicity indicated a significant association between the CTLA-4+49A/G variant and CD in Caucasian group (GG vs. GA+AA: OR=0.723, 95% CI=0.564-0.926, P=0.010). In Asian group, meta-analysis showed a significant association between the CTLA-4 CT60 variant and UC (AA vs. AG+GG: OR=0.375, 95% CI=0.163-0.861, P=0.021).
CONCLUSIONS: Based on the published literature, this meta-analysis suggests that the CTLA-4+49A/G variant may be related to CD susceptibility in Caucasians, and the CTLA-4 CT60 variant may be associated with UC susceptibility in Asians.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24374044     DOI: 10.1016/j.humimm.2013.12.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Authors:  Jagpal S Klair; Mohit Girotra; Laura F Hutchins; Kari D Caradine; Farshad Aduli; Mauricio Garcia-Saenz-de-Sicilia
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

Review 2.  IL-23R mutation is associated with ulcerative colitis: A systemic review and meta-analysis.

Authors:  Ling-Long Peng; Ying Wang; Feng-Ling Zhu; Wang-Dong Xu; Xue-Lei Ji; Jing Ni
Journal:  Oncotarget       Date:  2017-01-17

3.  Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report.

Authors:  Yasuki Hijikata; Yasuo Matsubara; Yasunori Ota; Lay Ahyoung Lim; Kenzaburo Tani; Yoshihiro Hirata; Hiroshi Yotsuyanagi
Journal:  Intern Med       Date:  2020-02-01       Impact factor: 1.271

4.  Association of Interleukin-23 receptor gene polymorphisms with susceptibility to Crohn's disease: A meta-analysis.

Authors:  Wang-Dong Xu; Qi-Bing Xie; Yi Zhao; Yi Liu
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

Review 5.  Concomitant Thyroid Disorders and Inflammatory Bowel Disease: A Literature Review.

Authors:  Toru Shizuma
Journal:  Biomed Res Int       Date:  2016-03-03       Impact factor: 3.411

6.  Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.

Authors:  Sara Hone Lopez; Gursah Kats-Ugurlu; Remco J Renken; Henk J Buikema; Marco R de Groot; Marijn C Visschedijk; Gerard Dijkstra; Mathilde Jalving; Jacco J de Haan
Journal:  Virchows Arch       Date:  2021-08-02       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.